A number of other research firms have also recently issued reports on ARAY. Zacks Investment Research raised Accuray from a hold rating to a buy rating and set a $5.50 target price for the company in a research note on Thursday, February 14th. BTIG Research reissued a hold rating on shares of Accuray in a research note on Wednesday, April 24th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Accuray has a consensus rating of Hold and a consensus price target of $5.13.
NASDAQ ARAY opened at $3.72 on Tuesday. Accuray has a 52-week low of $3.00 and a 52-week high of $5.40. The company has a debt-to-equity ratio of 3.06, a current ratio of 1.71 and a quick ratio of 1.03. The company has a market cap of $323.05 million, a P/E ratio of -13.29 and a beta of 1.91.
Accuray (NASDAQ:ARAY) last posted its earnings results on Tuesday, April 23rd. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Accuray had a negative return on equity of 25.91% and a negative net margin of 3.85%. The business had revenue of $103.22 million during the quarter, compared to analysts’ expectations of $104.02 million. As a group, sell-side analysts expect that Accuray will post -0.16 earnings per share for the current year.
In other news, CEO Joshua Levine sold 6,604 shares of the firm’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $4.54, for a total transaction of $29,982.16. Following the completion of the transaction, the chief executive officer now directly owns 1,033,593 shares of the company’s stock, valued at approximately $4,692,512.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.40% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Macquarie Group Ltd. grew its stake in shares of Accuray by 46.7% during the 4th quarter. Macquarie Group Ltd. now owns 7,810 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,487 shares in the last quarter. Citigroup Inc. grew its stake in shares of Accuray by 18.0% during the 1st quarter. Citigroup Inc. now owns 23,969 shares of the medical equipment provider’s stock worth $113,000 after acquiring an additional 3,663 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Accuray by 10.9% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 44,754 shares of the medical equipment provider’s stock worth $213,000 after acquiring an additional 4,392 shares in the last quarter. SEI Investments Co grew its stake in shares of Accuray by 40.4% during the 1st quarter. SEI Investments Co now owns 19,085 shares of the medical equipment provider’s stock worth $92,000 after acquiring an additional 5,490 shares in the last quarter. Finally, Swiss National Bank grew its stake in shares of Accuray by 5.8% during the 1st quarter. Swiss National Bank now owns 157,900 shares of the medical equipment provider’s stock worth $753,000 after acquiring an additional 8,600 shares in the last quarter. 81.24% of the stock is owned by institutional investors.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Featured Story: How the Consumer Price Index (CPI) is calculated?
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.